{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "offered-for-sale", "type": "definition", "offset": [114, 130]}, {"key": "the-business", "type": "clause", "offset": [172, 184]}, {"key": "with-respect-to", "type": "clause", "offset": [189, 204]}, {"key": "substantially-completed", "type": "definition", "offset": [228, 251]}, {"key": "development-efforts", "type": "clause", "offset": [256, 275]}, {"key": "as-of-the-closing-date", "type": "clause", "offset": [277, 299]}, {"key": "rights-of", "type": "definition", "offset": [549, 558]}, {"key": "a-third-party", "type": "clause", "offset": [559, 572]}], "size": 5, "samples": [{"hash": "abPECKgSdh0", "uri": "/contracts/abPECKgSdh0#current-product", "label": "Asset and Stock Purchase Agreement", "score": 31.340862423, "published": true}, {"hash": "iIKFZ4D5YQO", "uri": "/contracts/iIKFZ4D5YQO#current-product", "label": "Asset and Stock Purchase Agreement (Texas Instruments Inc)", "score": 23.1464750171, "published": true}, {"hash": "ixECzWN990Q", "uri": "/contracts/ixECzWN990Q#current-product", "label": "Asset and Stock Purchase Agreement (Sensata Technologies Holland, B.V.)", "score": 21.0, "published": true}], "snippet": "means any (i) Sensor Product or Control Product, or any component thereof, that was manufactured, marketed, sold, offered for sale, distributed or otherwise transferred by the Business, or with respect to which the Business has substantially completed its development efforts, as of the Closing Date and (ii) future Sensor Product, Control Product or component that is an extension, modification, derivation, replacement or successor of such Sensor Product, Control Product or component and does not infringe or misappropriate Intellectual Property Rights of a third party in a manner that is materially different from its predecessor.", "hash": "0ca4bdd4077da3eb3ac07bbe0d1b35e8", "id": 1}, {"snippet_links": [{"key": "the-product", "type": "clause", "offset": [34, 45]}, {"key": "signing-date", "type": "definition", "offset": [75, 87]}, {"key": "clinical-trials", "type": "definition", "offset": [104, 119]}], "size": 3, "samples": [{"hash": "d5Usmz7GOXU", "uri": "/contracts/d5Usmz7GOXU#current-product", "label": "Asset Purchase Agreement", "score": 31.340862423, "published": true}, {"hash": "g3aeSXi39IB", "uri": "/contracts/g3aeSXi39IB#current-product", "label": "Asset Purchase Agreement (Medivation, Inc.)", "score": 26.7631759069, "published": true}, {"hash": "9lfTzDSR9Gf", "uri": "/contracts/9lfTzDSR9Gf#current-product", "label": "Asset Purchase Agreement (Biomarin Pharmaceutical Inc)", "score": 26.7631759069, "published": true}], "snippet": "means the form and formulation of the Product being administered as of the Signing Date in the On-Going Clinical Trials.", "hash": "172d1a498781ce416eb67db071f9e3ec", "id": 2}, {"snippet_links": [{"key": "software-products", "type": "definition", "offset": [12, 29]}, {"key": "support-and-maintenance-services", "type": "clause", "offset": [130, 162]}, {"key": "end-of-life-product", "type": "definition", "offset": [196, 215]}, {"key": "sole-discretion", "type": "definition", "offset": [232, 247]}], "size": 3, "samples": [{"hash": "3d45mDsC9xI", "uri": "https://www.gsaadvantage.gov/ref_text/GS35F455AA/0YB8QI.3U1LL6_GS-35F-455AA_SESGSA7020230606.PDF", "label": "www.gsaadvantage.gov", "score": 11.71321013, "published": false}, {"hash": "hrZHsRwL9Vz", "uri": "https://www.gsaadvantage.gov/ref_text/GS35F455AA/0VY5GV.3ROIFM_GS-35F-455AA_SESGSA70.PDF", "label": "www.gsaadvantage.gov", "score": 10.401779603, "published": false}, {"hash": "9r0Mxqrf6Ha", "uri": "https://cdn2.hubspot.net/hubfs/3341329/Collabware%20Documents/Support%20and%20Maintenance%20Program%202019-01-01%20-%20Policy.pdf", "label": "cdn2.hubspot.net", "score": 9.5201916496, "published": false}], "snippet": "means those software products which have not been discontinued or retired by Collabware, and for which Collabware offers standard support and maintenance services. A Current Product may become an End of Life Product at Collabware\u2019s sole discretion.", "hash": "68c95b88c88593427e211725b27a7b37", "id": 3}, {"snippet_links": [{"key": "licensed-product", "type": "clause", "offset": [19, 35]}, {"key": "subject-of", "type": "clause", "offset": [48, 58]}, {"key": "product-nda", "type": "definition", "offset": [84, 95]}], "size": 3, "samples": [{"hash": "5sjZ0s11lyY", "uri": "/contracts/5sjZ0s11lyY#current-product", "label": "License and Development Agreement (Collegium Pharmaceutical, Inc)", "score": 27.6091718001, "published": true}, {"hash": "9AIc4DOAWE6", "uri": "/contracts/9AIc4DOAWE6#current-product", "label": "License and Development Agreement (Biodelivery Sciences International Inc)", "score": 27.6036960986, "published": true}, {"hash": "8MlfZxJ25vx", "uri": "https://ir.collegiumpharma.com/static-files/b8134e31-7f07-45c3-bae8-2a32180ad7c8", "label": "ir.collegiumpharma.com", "score": 7.7091033539, "published": false}], "snippet": "means that certain Licensed Product that is the subject of NDA 022266 (the \u201cCurrent Product NDA\u201d).", "hash": "8d2323e3ddb3c4a582f2f6dca0d15578", "id": 4}, {"snippet_links": [{"key": "clinical-trial", "type": "clause", "offset": [74, 88]}], "size": 3, "samples": [{"hash": "8vRlcWewcFQ", "uri": "/contracts/8vRlcWewcFQ#current-product", "label": "Licensing Agreement (Gilead Sciences Inc)", "score": 21.0, "published": true}, {"hash": "hli3jigqxin", "uri": "http://investors.gilead.com/static-files/538a7125-9214-4cc0-8700-d496d4727311", "label": "investors.gilead.com", "score": 9.4859685147, "published": false}], "snippet": "means the ten (10) milligram dosage formulation of ADV that was tested in clinical trial numbers GS-98-437 and GS-98-438.", "hash": "42b76084fbdcb99960da669bbb65fb48", "id": 5}, {"snippet_links": [{"key": "the-product", "type": "clause", "offset": [6, 17]}, {"key": "dosage-strength", "type": "definition", "offset": [47, 62]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [72, 96]}], "size": 3, "samples": [{"hash": "3m2FtOFHW7j", "uri": "/contracts/3m2FtOFHW7j#current-product", "label": "Merger Agreement (Salix Pharmaceuticals LTD)", "score": 25.5174537988, "published": true}], "snippet": "means the Product in the form, formulation and dosage strength existing as of the Effective Date.", "hash": "785605069660cd12009c3bdc0e38c3ad", "id": 6}, {"snippet_links": [{"key": "brand-product", "type": "definition", "offset": [14, 27]}, {"key": "by-a-third-party", "type": "clause", "offset": [189, 205]}, {"key": "in-development", "type": "definition", "offset": [227, 241]}, {"key": "for-sale", "type": "definition", "offset": [242, 250]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [270, 294]}], "size": 2, "samples": [{"hash": "gktSXsfW4uL", "uri": "/contracts/gktSXsfW4uL#current-product", "label": "Manufacturing Agreement (Ascendia Brands, Inc.)", "score": 21.0, "published": true}, {"hash": "3mrEFOweKXM", "uri": "/contracts/3mrEFOweKXM#current-product", "label": "Asset Purchase Agreement (Ascendia Brands, Inc.)", "score": 21.0, "published": true}], "snippet": "means (i) any Brand Product that Coty has sold, in any market, within the twelve (12) month period preceding the Effective Date, regardless whether such Product was manufactured by Coty or by a third party and (ii) any product in development for sale as a Brand Product as of the Effective Date.", "hash": "fae9dc4873704b1358bdbd3eec926f03", "id": 7}, {"snippet_links": [{"key": "licensed-product", "type": "clause", "offset": [19, 35]}, {"key": "subject-of", "type": "clause", "offset": [48, 58]}, {"key": "demonstration-samples", "type": "definition", "offset": [112, 133]}], "size": 2, "samples": [{"hash": "dN1JQ13Lezl", "uri": "https://ir.bdsi.com/static-files/924e2168-082f-4a03-8552-8ff2bbd1d59c", "label": "ir.bdsi.com", "score": 9.9952087611, "published": false}, {"hash": "gTam8l2D294", "uri": "https://ir.bdsi.com/static-files/25998290-3614-489e-a83c-8541946736be", "label": "ir.bdsi.com", "score": 9.9952087611, "published": false}], "snippet": "means that certain Licensed Product that is the subject of NDS Dossier ID: 183069 (the \u201cCurrent Product NDS\u201d). \u201cDemonstration Samples\u201d means a BEMA-based Product, lacking any API, that otherwise would constitute a Licensed Product and is used to", "hash": "9530ab9d61fe3c402a2d757962ca7499", "id": 8}, {"snippet_links": [{"key": "current-products", "type": "definition", "offset": [4, 20]}, {"key": "delivery-system", "type": "definition", "offset": [40, 55]}, {"key": "the-generator", "type": "clause", "offset": [93, 106]}, {"key": "exhibit-e", "type": "definition", "offset": [170, 179]}, {"key": "by-medtronic", "type": "clause", "offset": [199, 211]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [242, 266]}, {"key": "date-of", "type": "clause", "offset": [274, 281]}, {"key": "transfer-to", "type": "clause", "offset": [297, 308]}, {"key": "change-to", "type": "definition", "offset": [374, 383]}, {"key": "the-system", "type": "clause", "offset": [384, 394]}, {"key": "intended-use", "type": "clause", "offset": [430, 442]}, {"key": "control-mechanism", "type": "definition", "offset": [456, 473]}, {"key": "for-clarity", "type": "clause", "offset": [512, 523]}, {"key": "new-indication", "type": "definition", "offset": [577, 591]}, {"key": "improved-products", "type": "clause", "offset": [605, 622]}, {"key": "wet-electrode-products", "type": "definition", "offset": [627, 649]}], "size": 2, "samples": [{"hash": "et2Jr1dmq2W", "uri": "/contracts/et2Jr1dmq2W#current-product", "label": "License Agreement (Urologix Inc)", "score": 22.9849418207, "published": true}, {"hash": "eq7j4XeoAuO", "uri": "/contracts/eq7j4XeoAuO#current-product", "label": "License Agreement (Urologix Inc)", "score": 22.6865160849, "published": true}], "snippet": "or \u201cCurrent Products\u201d means the therapy delivery system or the components thereof, including the generator, footswitch, and the disposable and telescope, as described on Exhibit E and commercialized by Medtronic under the Prostiva\u00ae trademark as of the Effective Date or the date of the Regulatory Transfer to Urologix, together with any Improvements that do not result in a change to the system\u2019s (or a component of the system\u2019s) intended use, indication, control mechanism, operating principle, or energy type. For clarity, Current Product and Current Products do not include New Indication Products, RF Improved Products, or Wet Electrode Products.", "hash": "cf9c886373dc60159b6de6af2b3c973d", "id": 9}, {"snippet_links": [{"key": "other-products", "type": "clause", "offset": [157, 171]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [251, 275]}, {"key": "new-product", "type": "definition", "offset": [284, 295]}, {"key": "following-the", "type": "definition", "offset": [296, 309]}, {"key": "third-anniversary", "type": "definition", "offset": [310, 327]}, {"key": "initial-announcement", "type": "definition", "offset": [335, 355]}, {"key": "each-case", "type": "definition", "offset": [381, 390]}, {"key": "from-time-to-time", "type": "clause", "offset": [403, 420]}], "size": 2, "samples": [{"hash": "LMJKXQtLHi", "uri": "/contracts/LMJKXQtLHi#current-product", "label": "Distribution Agreement (Danka Business Systems PLC)", "score": 18.0, "published": true}, {"hash": "7ibekyUVaan", "uri": "/contracts/7ibekyUVaan#current-product", "label": "Distribution Agreement (Danka Business Systems PLC)", "score": 18.0, "published": true}], "snippet": "means any manufactured, remanufactured or salvaged Black & White and Accent Color Equipment, Software, Supply, Accessory or Spare Part (excluding toners and other products manufactured for use in other manufacturer's equipment) assembled for NexPress as of the Effective Date and any New Product following the third anniversary of the Initial Announcement with respect thereto, in each case as modified from time to time by any Enhancements thereto.", "hash": "a6b37237ad6d1f8596b84247a821143e", "id": 10}], "next_curs": "ClwSVmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjgLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIYY3VycmVudC1wcm9kdWN0IzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 68, "snippet": "means any (i) Sensor Product or Control Product, or any component thereof, that was manufactured, marketed, sold, offered for sale, distributed or otherwise transferred by the Business, or with respect to which the Business has substantially completed its development efforts, as of the Closing Date and (ii) future Sensor Product, Control Product or component that is an extension, modification, derivation, replacement or successor of such Sensor Product, Control Product or component and does not infringe or misappropriate Intellectual Property Rights of a third party in a manner that is materially different from its predecessor.", "title": "Current Product", "id": "current-product", "examples": ["Seller shall invoice Buyer within 60 days after each shipment of such <strong>Current Product</strong> for the applicable Have Made Costs for the <strong>Current Products</strong> included in such shipment.", "Buyer shall not, however, be required to recall or destroy price lists, literature or advertising for the <strong>Current Product</strong> bearing Seller Trademarks and Tradenames.", "Neither Seller nor any of its Affiliates has received any written notice from any Governmental Authority claiming that the research, development, manufacture, or use of BMN-673 and the <strong>Current Product</strong> is not in material compliance with all applicable Laws.", "The Acquired Assets constitute all of the rights, property and assets that are owned and controlled by Seller or any of its Affiliates as of the Closing Date and are necessary for the development and commercialization of the <strong>Current Product</strong>.", "None of the Excluded Assets (other than certain employees of Seller or any of its Affiliates) are material to the development and commercialization of the <strong>Current Product</strong>.", "In the event that InSite is not able to obtain such writing, InSite promptly shall establish alternative arrangements reasonably acceptable to Inspire whereby Inspire\u2019s access to supply of the <strong>Current Product</strong> in commercially reasonable amounts for launch and marketing thereof is not impaired by the lack of such writing.", "Promptly after the Transfer Date, Salix will use commercially reasonable efforts to provide Napo a list and contact information for Third Parties with whom Salix has any material managed care contracts, commercial insurance contract, contracts providing chargebacks, and government contracts that covered the <strong>Current Product</strong> prior to the Transfer Date.", "With respect to the Licensed Products, upon assignment of the <strong>Current Product</strong> NDA to Collegium (\u201cNDA Assignment\u201d), Collegium agrees, at its sole cost and expense, to maintain all Marketing Authorizations and Governmental Approvals in the Territory throughout the Term, including submitting any supplemental applications, annual reports, variations or renewals thereof that are required by Applicable Law to be obtained in order to maintain the Marketing Authorizations and Governmental Approvals.", "The Elan Companies or its Affiliates have filed with the FDA all required notices, supplemental applications and annual or other reports, including adverse experience reports, with respect to each IND or NDA relating to the Product or a <strong>Current Product</strong> Improvement.", "Salix shall use commercially reasonable efforts to secure the foregoing rights of inspection from Salix\u2019s trial sites and other contractors (including manufacturers of the Licensed Compound or <strong>Current Product</strong>) for the Licensed Compound and <strong>Current Product</strong>."], "related": [["licensed-product", "Licensed Product", "Licensed Product"], ["generic-product", "Generic Product", "Generic Product"], ["diagnostic-product", "Diagnostic Product", "Diagnostic Product"], ["end-product", "End product", "End product"], ["hemp-product", "Hemp product", "Hemp product"]], "related_snippets": [], "updated": "2025-07-06T21:58:36+00:00"}, "json": true, "cursor": ""}}